Aberdeen Group plc Purchases New Position in ADMA Biologics Inc $ADMA

Aberdeen Group plc purchased a new stake in shares of ADMA Biologics Inc (NASDAQ:ADMA) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 531,782 shares of the biotechnology company’s stock, valued at approximately $9,684,000. Aberdeen Group plc owned about 0.22% of ADMA Biologics as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the company. Blue Trust Inc. lifted its holdings in ADMA Biologics by 53.6% during the 2nd quarter. Blue Trust Inc. now owns 2,762 shares of the biotechnology company’s stock valued at $50,000 after purchasing an additional 964 shares during the last quarter. Maryland State Retirement & Pension System lifted its holdings in ADMA Biologics by 1.7% during the 2nd quarter. Maryland State Retirement & Pension System now owns 70,160 shares of the biotechnology company’s stock valued at $1,278,000 after purchasing an additional 1,143 shares during the last quarter. KLP Kapitalforvaltning AS lifted its holdings in ADMA Biologics by 7.3% during the 2nd quarter. KLP Kapitalforvaltning AS now owns 49,700 shares of the biotechnology company’s stock valued at $905,000 after purchasing an additional 3,400 shares during the last quarter. 111 Capital bought a new position in ADMA Biologics during the 2nd quarter valued at about $278,000. Finally, Vaughan Nelson Investment Management L.P. bought a new position in shares of ADMA Biologics in the second quarter worth about $32,786,000. 75.68% of the stock is owned by institutional investors.

ADMA Biologics Trading Up 0.9%

Shares of NASDAQ ADMA opened at $15.09 on Thursday. ADMA Biologics Inc has a 1-year low of $13.50 and a 1-year high of $25.67. The company has a market cap of $3.60 billion, a PE ratio of 17.55 and a beta of 0.47. The company has a current ratio of 5.33, a quick ratio of 2.78 and a debt-to-equity ratio of 0.21. The company has a 50-day moving average of $16.08 and a two-hundred day moving average of $18.45.

ADMA Biologics (NASDAQ:ADMA) last announced its earnings results on Wednesday, August 6th. The biotechnology company reported $0.15 earnings per share for the quarter, topping analysts’ consensus estimates of $0.14 by $0.01. The company had revenue of $121.98 million during the quarter, compared to the consensus estimate of $121.77 million. ADMA Biologics had a net margin of 44.06% and a return on equity of 41.01%. The company’s revenue was up 13.8% on a year-over-year basis. During the same period in the previous year, the firm posted $0.13 earnings per share. As a group, equities analysts expect that ADMA Biologics Inc will post 0.51 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “buy (b-)” rating on shares of ADMA Biologics in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating and three have issued a Buy rating to the company’s stock. According to data from MarketBeat, ADMA Biologics has an average rating of “Buy” and a consensus price target of $27.67.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.